CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies


Posted in: Medical Research News | Medical Condition News | Pharmaceutical News

Tags: Acute Lymphoblastic Leukemia, Adenosine, AIDS, Allergy, Antibodies, Antibody, Antigen, Arthritis, Autoimmunity, biology, Biomarker, Bladder Cancer, Brain, Brain Cancer, Brain Metastases, Breast Cancer, Cancer, Carcinoma, Cell, Cervical Cancer, Chemokines, Chemoradiotherapy, Chemotherapy, Clinical Trial, Colon Cancer, Colorectal, Colorectal Cancer, CT, Doxorubicin, Epstein-Barr Virus, Gastric Cancer, Gene, Genes, Glioblastoma, Head and Neck Cancer, HIV, Hodgkin Lymphoma, Hospital, Immunology, Immunosuppression, Immunotherapies, Immunotherapy, Infectious Diseases, Kidney Cancer, Leukemia, Lung Cancer, Lymphoma, Macrophage, Macrophages, Medical School, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Musculoskeletal, Myeloma, Neutrophils, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma, Skin Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma, Stem Cell, Translational, Tumor, Tumorigenesis, Ultrasound, Uterine Cancer, Vaccine, Virus